BofA/Merrill Lynch Downgrades Optimer Pharmaceuticals (OPTR) Two-Notches to Underperform
Tweet Send to a FriendGet Alerts OPTR Hot Sheet
Price: $14.38 --0%
Rating Summary:
5 Buy, 7 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 0 | Down: 0 | New: 8
Rating Summary:
5 Buy, 7 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 0 | Down: 0 | New: 8
Trade OPTR Now!
BofA/Merrill Lynch downgraded Optimer Pharmaceuticals (NASDAQ: OPTR) from Buy to Underperform.
For an analyst ratings summary and ratings history on Optimer Pharmaceuticals click here. For more ratings news on Optimer Pharmaceuticals click here.
Shares of Optimer Pharmaceuticals closed at $15.51 yesterday, with a 52 week range of $10.00-$17.95.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
For an analyst ratings summary and ratings history on Optimer Pharmaceuticals click here. For more ratings news on Optimer Pharmaceuticals click here.
Shares of Optimer Pharmaceuticals closed at $15.51 yesterday, with a 52 week range of $10.00-$17.95.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- UPDATE: JPMorgan Cuts SodaStream (SODA) to Neutral, 'Stock No Longer Cheap'
- UPDATE: Sterne Agee Downgrades Beazer Homes (BZH) to Neutral
- Goldman Sachs Downgrades WellCare Health Plans (WCG) to Neutral
Create E-mail Alert Related Categories
Downgrades, Hot DowngradesRelated Entities
Merrill Lynch, Bank of America
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
